49
Participants
Start Date
March 31, 2012
Primary Completion Date
July 31, 2017
Study Completion Date
March 12, 2018
FOLFOXIRI plus Bevacizumab
"* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months)."
Chemoradiotherapy plus Bevacizumab
"* FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment;~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks;~* BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles)."
Irccs Istituto Oncologico Veneto, Padua
Dipartimento Oncologico AUSL 7, Siena
Polo Oncologico Area Vasta Nord Ovest, Pisa
ausl5 di Pisa, Pontedera
Azienda Ospedaliero, Universitaria Pisana
OTHER